Stockscreener 앱 받기
2.39
2.45%
-0.06
Ac Immune Sa 주식(ACIU)의 최신 뉴스
AC Immune SA (HAM:IMR) Stock Price, Trades & News - GuruFocus
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. - Stock Titan
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Best Momentum Stock to Buy for September 30th - Zacks Investment Research
Average basic shares outstanding of AC Immune SA – HAN:IMR - TradingView
Long term debt to total equity ratio of AC Immune SA – HAN:IMR - tradingview.com
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals - Yahoo Finance
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha
H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com
AC Immune says ACI-7104 shows durable immunogenicity - The Pharma Letter
AC Immune (NasdaqGM:ACIU) Stock Forecast & Analyst Predictions - Simply Wall Street
AC Immune SA (ACIU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response - Benzinga
AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha
AC Immune reports positive phase 2 trial results for ACI-7104 - Investing.com
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com
AC Immune reports positive phase 2 trial results for Parkinson’s drug - Investing.com UK
Experimental Parkinson’s treatment from AC Immune (NASDAQ: ACIU) sparks immune response in early trial - Stock Titan
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - Yahoo Finance UK
After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - GlobeNewswire
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - Zacks Investment Research
AC Immune SA Share PriceACIU, RNS News, Articles, Quotes, & Charts (NASDAQ:ACIU) - Proactive financial news
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus - TipRanks
AC Immune SA (NASDAQ: ACIU) Schedules October 2 Vote for Tom Graney's Board Nomination - Kalkine Media
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board - TipRanks
Parkinson's drug Fast Tracked as AC Immune (NASDAQ: ACIU) plans board changes - Stock Titan
AC Immune Ltd (NASDAQ: ACIU) Share Price, ACIU Stock News, ACIU Share Price & Updates - kalkine.ca
AC Immune reports positive phase 1 data for ACI‑19764 - PharmaTimes
AC Immune stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Positive Ph1 results for AC Immune's NLRP3 inflammasome inhibitor - pharmaphorum
AC (ACIU) Financial Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; After Earnings: The Market Price Moves 2.33% Higher on the DayConsensus Forecast Report - vinanet.vn
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline - Benzinga
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
AC Immune's NLRP3 inhibitor reaches brain with safety intact in first human study - AllSci
AC Immune shares rise after encouraging early Phase 1 data for ACI-19764 - Yahoo Finance
AC Immune stock gains on early Phase 1 trial results By Investing.com - Investing.com Australia
AC Immune stock gains on early Phase 1 trial results - Investing.com
AC Immune stock gains on early Phase 1 trial results - Investing.com India
4.22%
자본화:
|
볼륨(24시간):